{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T13:18:57Z","timestamp":1775308737313,"version":"3.50.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2015,3,5]],"date-time":"2015-03-05T00:00:00Z","timestamp":1425513600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hum Genet"],"published-print":{"date-parts":[[2015,5]]},"DOI":"10.1038\/jhg.2015.11","type":"journal-article","created":{"date-parts":[[2015,3,5]],"date-time":"2015-03-05T07:13:38Z","timestamp":1425539618000},"page":"253-258","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Incidence and clinical importance of BCR-ABL1 mutations in Iranian patients with chronic myeloid leukemia on imatinib"],"prefix":"10.1038","volume":"60","author":[{"given":"Golale","family":"Rostami","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad","family":"Hamid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Majid","family":"Yaran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohsen","family":"Khani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Morteza","family":"Karimipoor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,3,5]]},"reference":[{"key":"BFjhg201511_CR1","doi-asserted-by":"publisher","first-page":"4010","DOI":"10.1182\/blood-2003-12-4111","volume":"103","author":"B Calabretta","year":"2004","unstructured":"Calabretta, B. & Perrotti, D. The biology of CML blast crisis. Blood 103, 4010\u20134022 (2004).","journal-title":"Blood"},{"key":"BFjhg201511_CR2","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1056\/NEJMoa011573","volume":"346","author":"H Kantarjian","year":"2002","unstructured":"Kantarjian, H., Sawyers, C., Hochhaus, A., Guilhot, F., Schiffer, C., Gambacorti-Passerini, C. et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. New Engl. J. Med 346, 645\u2013652 (2002).","journal-title":"New Engl. J. Med"},{"key":"BFjhg201511_CR3","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1634\/theoncologist.2007-0170","volume":"13","author":"P Ramirez","year":"2008","unstructured":"Ramirez, P. & DiPersio, J. F. Therapy options in imatinib failures. Oncologist 13, 424\u2013434 (2008).","journal-title":"Oncologist"},{"key":"BFjhg201511_CR4","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1186\/1756-8722-4-7","volume":"4","author":"W Wongboonma","year":"2011","unstructured":"Wongboonma, W., Thongnoppakhun, W. & Auewarakul, C. U. A single-tube allele specific-polymerase chain reaction to detect T315I resistant mutation in chronic myeloid leukemia patients. J. Hematol. Oncol. 4, 1756\u20131763 (2011).","journal-title":"J. Hematol. Oncol."},{"key":"BFjhg201511_CR5","doi-asserted-by":"publisher","first-page":"e55717","DOI":"10.1371\/journal.pone.0055717","volume":"8","author":"Z Iqbal","year":"2013","unstructured":"Iqbal, Z., Aleem, A., Iqbal, M., Naqvi, M. I., Gill, A., Taj, A. S. et al. Sensitive detection of pre-existing BCR-ABL kinase domain mutations in CD34+ cells of newly diagnosed chronic-phase chronic myeloid leukemia patients is associated with imatinib resistance: implications in the post-imatinib era. PLoS ONE 8, e55717 (2013).","journal-title":"PLoS ONE"},{"key":"BFjhg201511_CR6","doi-asserted-by":"publisher","first-page":"347","DOI":"10.3324\/haematol.2010.039560","volume":"96","author":"MS Mathisen","year":"2011","unstructured":"Mathisen, M. S., Kantarjian, H. M., Cortes, J. & Jabbour, E. Mutant BCR-ABL clones in chronic myeloid leukemia. Haematologica 96, 347\u2013349 (2011).","journal-title":"Haematologica"},{"key":"BFjhg201511_CR7","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1002\/hon.894","volume":"27","author":"SH Kim","year":"2009","unstructured":"Kim, S. H., Kim, D., Kim, D. W., Goh, H. G., Jang, S. E., Lee, J. et al. Analysis of Bcr\u2010Abl kinase domain mutations in Korean chronic myeloid leukaemia patients: poor clinical outcome of P\u2010loop and T315I mutation is disease phase dependent. Hematol. Oncol. 27, 190\u2013197 (2009).","journal-title":"Hematol. Oncol."},{"key":"BFjhg201511_CR8","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1038\/sj.leu.2404318","volume":"20","author":"E Jabbour","year":"2006","unstructured":"Jabbour, E., Kantarjian, H., Jones, D., Talpaz, M., Bekele, N., O'Brien, S. et al. Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate. Leukemia 20, 1767\u20131773 (2006).","journal-title":"Leukemia"},{"key":"BFjhg201511_CR9","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1007\/s00277-006-0171-8","volume":"85","author":"Y Wei","year":"2006","unstructured":"Wei, Y., Hardling, M., Olsson, B., Hezaveh, R., Ricksten, A., Stockelberg, D. et al. Not all imatinib resistance in CML are BCR-ABL kinase domain mutations. Ann. Hematol. 85, 841\u2013847 (2006).","journal-title":"Ann. Hematol."},{"key":"BFjhg201511_CR10","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1182\/blood-2006-02-005686","volume":"108","author":"M Baccarani","year":"2006","unstructured":"Baccarani, M., Saglio, G., Goldman, J., Hochhaus, A., Simonsson, B., Appelbaum, F. et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 108, 1809\u20131820 (2006).","journal-title":"Blood"},{"key":"BFjhg201511_CR11","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1182\/blood-2010-12-326405","volume":"118","author":"S Soverini","year":"2011","unstructured":"Soverini, S., Hochhaus, A., Nicolini, F. E., Gruber, F., Lange, T., Saglio, G. et al. BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood 118, 1208\u20131215 (2011).","journal-title":"Blood"},{"key":"BFjhg201511_CR12","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.yexmp.2012.01.007","volume":"92","author":"W Wongboonma","year":"2012","unstructured":"Wongboonma, W., Thongnoppakhun, W. & Auewarakul, C. U. BCR-ABL kinase domain mutations in tyrosine kinase inhibitors-na\u00efve and-exposed Southeast Asian chronic myeloid leukemia patients. Exp. Mol. Pathol. 92, 259\u2013265 (2012).","journal-title":"Exp. Mol. Pathol."},{"key":"BFjhg201511_CR13","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1182\/blood-2005-07-2815","volume":"108","author":"M Koptyra","year":"2006","unstructured":"Koptyra, M., Falinski, R., Nowicki, M. O., Stoklosa, T., Majsterek, I., Nieborowska-Skorska, M. et al. BCR\/ABL kinase induces self-mutagenesis via reactive oxygen species to encode imatinib resistance. Blood 108, 319\u2013327 (2006).","journal-title":"Blood"},{"key":"BFjhg201511_CR14","doi-asserted-by":"publisher","first-page":"4250","DOI":"10.1182\/blood-2005-11-4406","volume":"107","author":"RD Press","year":"2006","unstructured":"Press, R. D., Love, Z., Tronnes, A. A., Yang, R., Tran, T., Mongoue-Tchokote, S. et al. BCR-ABL mRNA levels at and after the time of a complete cytogenetic response (CCR) predict the duration of CCR in imatinib mesylate\u2013treated patients with CML. Blood 107, 4250\u20134256 (2006).","journal-title":"Blood"},{"key":"BFjhg201511_CR15","doi-asserted-by":"publisher","first-page":"4","DOI":"10.2353\/jmoldx.2009.080095","volume":"11","author":"D Jones","year":"2009","unstructured":"Jones, D., Kamel-Reid, S., Bahler, D., Dong, H., Elenitoba-Johnson, K., Press, R. et al. Laboratory practice guidelines for detecting and reporting BCR-ABL drug resistance mutations in chronic myelogenous leukemia and acute lymphoblastic leukemia: a report of the Association for Molecular Pathology. J. Mol. Diagn 11, 4\u201311 (2009).","journal-title":"J. Mol. Diagn"},{"key":"BFjhg201511_CR16","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s00277-010-1039-5","volume":"90","author":"Y Qin","year":"2011","unstructured":"Qin, Y., Chen, S., Jiang, B., Jiang, Q., Jiang, H., Li, J. et al. Characteristics of BCR\u2013ABL kinase domain point mutations in Chinese imatinib-resistant chronic myeloid leukemia patients. Ann. Hematol. 90, 47\u201352 (2011).","journal-title":"Ann. Hematol."},{"key":"BFjhg201511_CR17","doi-asserted-by":"publisher","first-page":"7374","DOI":"10.1158\/1078-0432.CCR-06-1516","volume":"12","author":"S Soverini","year":"2006","unstructured":"Soverini, S., Colarossi, S., Gnani, A., Rosti, G., Castagnetti., F., Poerio., A. et al. Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia. Clin. Cancer Res. 12, 7374\u20137379 (2006).","journal-title":"Clin. Cancer Res."},{"key":"BFjhg201511_CR18","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1089\/gtmb.2012.0147","volume":"16","author":"A Awidi","year":"2012","unstructured":"Awidi, A., Ababneh, N., Magablah, A., Bsoul, N., Mefleh, R., Marei, L. et al. ABL kinase domain mutations in patients with chronic myeloid leukemia in Jordan. Genet. Test. Mol. Biomarkers 16, 1317\u20131321 (2012).","journal-title":"Genet. Test. Mol. Biomarkers"},{"key":"BFjhg201511_CR19","doi-asserted-by":"publisher","first-page":"4806","DOI":"10.1200\/JCO.2008.16.9953","volume":"26","author":"JS Khorashad","year":"2008","unstructured":"Khorashad, J. S., de Lavallade, H., Apperley, J. F., Milojkovic, D., Reid, A. G., Bua, M. et al. Finding of kinase domain mutations in patients with chronic phase chronic myeloid leukemia responding to imatinib may identify those at high risk of disease progression. J. Clin. Oncol. 26, 4806\u20134813 (2008).","journal-title":"J. Clin. Oncol."},{"key":"BFjhg201511_CR20","doi-asserted-by":"publisher","first-page":"2190","DOI":"10.1038\/sj.leu.2402741","volume":"16","author":"A Hochhaus","year":"2002","unstructured":"Hochhaus, A., Kreil, S., Corbin, A., La Rosee, P., M\u00fcller, M., Lahaye, T. et al. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia 16, 2190\u20132196 (2002).","journal-title":"Leukemia"},{"key":"BFjhg201511_CR21","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/S0092-8674(03)00190-9","volume":"112","author":"M Azam","year":"2003","unstructured":"Azam, M., Latek, R. R. & Daley, G. Q. Mechanisms of autoinhibition and STI-571\/imatinib resistance revealed by mutagenesis of BCR-ABL. Cell 112, 831\u2013843 (2003).","journal-title":"Cell"},{"key":"BFjhg201511_CR22","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1200\/JCO.2008.19.8853","volume":"27","author":"S Redaelli","year":"2009","unstructured":"Redaelli, S., Piazza, R., Rostagno, R., Magistroni, V., Perini, P., Marega, M. et al. Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR\/ABL mutants. J. Clin. Oncol. 27, 469\u2013471 (2009).","journal-title":"J. Clin. Oncol."},{"key":"BFjhg201511_CR23","doi-asserted-by":"publisher","first-page":"e169","DOI":"10.1200\/JCO.2009.26.4945","volume":"28","author":"P Laneuville","year":"2010","unstructured":"Laneuville, P., DiLea, C., Yin, O. Q., Woodman, R. C., Mestan, J. & Manley, P. W. Comparative In vitro cellular data alone are insufficient to predict clinical responses and guide the choice of BCR-ABL inhibitor for treating imatinib-resistant chronic myeloid leukemia. J. Clin. Oncol. 28, e169\u2013e171 (2010).","journal-title":"J. Clin. Oncol."},{"key":"BFjhg201511_CR24","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.3109\/10428191003729741","volume":"51","author":"P Sharma","year":"2010","unstructured":"Sharma, P., Mohanty, S., Kochupillai, V. & Kumar, L. Mutations in ABL kinase domain are associated with inferior progression-free survival. Leuk. Lymphoma 51, 1072\u20131078 (2010).","journal-title":"Leuk. Lymphoma"}],"container-title":["Journal of Human Genetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/jhg201511.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/jhg201511","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/jhg201511.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T17:33:37Z","timestamp":1684431217000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/jhg201511"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3,5]]},"references-count":24,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,5]]}},"alternative-id":["BFjhg201511"],"URL":"https:\/\/doi.org\/10.1038\/jhg.2015.11","relation":{},"ISSN":["1434-5161","1435-232X"],"issn-type":[{"value":"1434-5161","type":"print"},{"value":"1435-232X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,3,5]]},"assertion":[{"value":"2 September 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2014","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2015","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2015","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}